Georgetown University, 3700 O St NW, Washington, DC, 20057, USA.
Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India.
Syst Rev. 2018 Feb 14;7(1):28. doi: 10.1186/s13643-018-0688-7.
This is the protocol for a systematic review (and meta-analysis) of an intervention. The primary objective of this systematic review will be to assess the benefits and harms of pharmacological therapies (pharmacotherapies) for the management of fatigue in adults with CLD of any etiology. The effects of pharmacological therapies on fatigue in CLD will be compared against those of placebo, no intervention, or non-pharmacological interventions. Specifically, this review will examine whether pharmacological therapies improve CLD-associated fatigue, and if they do, what key elements are associated with their effectiveness. The results of this systematic review will assist clinicians, policy-makers, researchers, and people with CLD in decision-making on how best to manage fatigue and its associated symptoms.
MEDLINE, SCOPUS, EMBASE, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform, CENTRAL (The Cochrane Library), ClinicalTrials.gov, reference lists of articles and conference proceedings will be searched for relevant studies. No language or date restrictions will be applied. Eligible studies will include adults with CLD of any etiology. Included studies will be randomized controlled trials. From included studies, data on participant characteristics, study design, setting, research ethics compliance, and intervention outcomes will be extracted. Risk of bias in included studies will be assessed using the Cochrane Risk of Bias Tool. A random-effects meta-analysis will be conducted. If substantial or considerable levels of heterogeneity are detected, analysis will be limited to a narrative synthesis.
This systematic review will examine the effectiveness of pharmacological therapies on fatigue reduction in people with CLD. Such therapies may be more effective than non-pharmacological interventions in treating fatigue symptoms in CLD. Evidence derived from the findings of this study will guide future practice, policy, and research.
PROSPERO, CRD42017076957.
这是一项干预措施的系统评价（和荟萃分析）方案。本次系统评价的主要目的是评估各种病因的慢性肝病（CLD）成人患者使用药物疗法（药物治疗）管理疲劳的获益与危害。药物治疗对 CLD 疲劳的影响将与安慰剂、无干预或非药物干预进行比较。具体而言，本次综述将检查药物疗法是否能改善 CLD 相关的疲劳，如果可以，哪些关键因素与它们的有效性相关。本次系统评价的结果将有助于临床医生、决策者、研究人员和 CLD 患者在如何最好地管理疲劳及其相关症状方面做出决策。
将对 MEDLINE、SCOPUS、EMBASE、EU 临床试验注册处、世界卫生组织国际临床试验注册平台、CENTRAL（考科兰图书馆）、ClinicalTrials.gov 以及文章和会议记录的参考文献进行检索，以查找相关研究。不会对语言或日期进行限制。合格的研究将包括任何病因的 CLD 成人患者。纳入的研究将是随机对照试验。从纳入的研究中，将提取参与者特征、研究设计、设置、研究伦理合规性和干预结果的数据。将使用 Cochrane 偏倚风险工具评估纳入研究的偏倚风险。将进行随机效应荟萃分析。如果检测到实质性或相当大程度的异质性，分析将限于叙述性综合。
本次系统评价将检查药物疗法在降低 CLD 患者疲劳方面的有效性。与非药物干预相比，此类疗法可能更能有效治疗 CLD 疲劳症状。本研究结果得出的证据将指导未来的实践、政策和研究。
PROSPERO，CRD42017076957。
